354 related articles for article (PubMed ID: 28129822)
1. [Antimicrobial spectrum of dalbavancin. Mechanism of action and in vitro activity against Gram-positive microorganisms].
Cercenado E
Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():9-14. PubMed ID: 28129822
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
3. [Update on antibiotic resistance in Gram-positive bacteria].
Lozano C; Torres C
Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():2-8. PubMed ID: 28129816
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
Gales AC; Sader HS; Jones RN
Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
Rolston KV; Wang W; Nesher L; Shelburne SA; Prince RA
J Antibiot (Tokyo); 2016 May; 69(5):381-7. PubMed ID: 26626876
[TBL] [Abstract][Full Text] [Related]
6. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
Streit JM; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
[TBL] [Abstract][Full Text] [Related]
7. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
[TBL] [Abstract][Full Text] [Related]
8. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
9. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
10. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
11. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
Streit JM; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2004 Feb; 48(2):137-43. PubMed ID: 14972384
[TBL] [Abstract][Full Text] [Related]
12. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.
Koeth LM; DiFranco-Fisher JM; McCurdy S
J Vis Exp; 2015 Sep; (103):. PubMed ID: 26381422
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.
Sader HS; Mendes RE; Pfaller MA; Flamm RK
J Antimicrob Chemother; 2019 May; 74(5):1306-1310. PubMed ID: 30753485
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
[TBL] [Abstract][Full Text] [Related]
15. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
Riccobono E; Giani T; Baldi G; Arcangeli S; Antonelli A; Tellone V; Del Vecchio A; De Joannon AC; Rossolini GM
Int J Antimicrob Agents; 2022 Feb; 59(2):106503. PubMed ID: 34929289
[TBL] [Abstract][Full Text] [Related]
16. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
[TBL] [Abstract][Full Text] [Related]
17. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
[TBL] [Abstract][Full Text] [Related]
18. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
19. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
Aktaş G; Bozdoğan B; Derbentli S
Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
[TBL] [Abstract][Full Text] [Related]
20. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
Biedenbach DJ; Bell JM; Sader HS; Turnidge JD; Jones RN
Antimicrob Agents Chemother; 2009 Mar; 53(3):1260-3. PubMed ID: 19124664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]